



*Empowered lives.
Resilient nations.*

USING LAW TO ACCELERATE TREATMENT ACCESS IN SOUTH AFRICA

An Analysis of Patent, Competition and Medicines Law

United Nations Development Programme



Using Law to Accelerate Treatment Access in South Africa:

AN ANALYSIS OF PATENT, COMPETITION AND MEDICINES LAW

Chan Park, Achal Prabhala and Jonathan Berger

October 2013

Copyright © United Nations Development Programme, October 2013

One United Nations Plaza
New York, NY 10017
U.S.A.

Website: <http://www.undp.org/>

DISCLAIMER:

The views expressed in this publication are those of the authors and do not necessarily represent those of the United Nations, including UNDP, or their Member States.



ABOUT THE STUDY

This study was conceived and commissioned by UNDP's Regional Service Centre for Eastern and Southern Africa in 2007 as one of a number of country studies initiated to examine the extent to which the domestic legal and regulatory environment enabled countries in Africa to increase access to essential medicines. A first version of the paper served a background document for a consultation organised by UNDP in November 2007, for government officials from Ghana, South Africa and Zambia which took place in Pretoria. The paper was updated in 2013 by the authors and edited by Kajal Bhardwaj. The authors thank representatives from government, industry and civil society for sharing their time and insights, and are particularly grateful to SECTION27 (formerly known as the AIDS Law Project) for research and logistical support. The authors are grateful to Kajal Bhardwaj for her helpful suggestions and editorial review and to Tenu Avafia and Katie Kirk from UNDP's HIV, Health and Development Practice in New York who oversaw the publication process.



TABLE OF CONTENTS

Foreword	9
Executive Summary	11
1. Introduction	15
1.1 Why TRIPS flexibilities?	15
1.2 South Africa and treatment for HIV infection	19
1.3 TRIPS flexibilities and the South African legal system.....	22
2. Analysis of the South African Patent System	23
2.1 Patent Criteria	25
2.1.1 Novelty	26
2.1.1.1 New uses of known substances	28
2.1.1.2 Selection patents.....	29
2.1.2 Inventive step.....	31
2.1.3 Industrial application/utility	34
2.1.4. Summary of policy options relating to patentability criteria.....	36
2.2 Defining limited exceptions to patent rights, including for compulsory licensing.....	37
2.2.1 Exclusions expressly allowed under TRIPS.....	37
2.2.2. Other exclusions from patentability	38
2.2.2.1 Naturally occurring substances	40
2.2.2.2 New forms of known substances.....	41
2.2.2.3 Mere admixtures.....	44
2.2.3. How effective are these exclusions from patentability?.....	45
2.2.4 Summary of policy options relating to exclusions from patentability	45
2.3. Disclosure of information in patent applications.....	46
2.3.1. Flexibilities in TRIPS with with respect to disclosure of information in parent applications.....	47
2.3.1.1 Disclosure of best mode	48
2.3.1.2 Disclosure of the status of foreign applications	48
2.3.1.3 Other disclosure requirements.....	50
2.3.1.4 Duty to disclose all relevant material prior art.....	50
2.3.1.5 Duty to disclose international non-proprietary names for pharmaceutical applications	51
2.3.1.6 Duty to disclose whether an application relates to a disease of public health priority.....	52



TABLE OF CONTENTS

2.3.2	Summary of policy options with with respect to disclosure of information in parent applications	52
2.4	Patent examination and oppositions	53
2.5	Limited exceptions to patent rights.....	55
2.5.1	Early working and parallel imports	55
2.5.2	Other exceptions.....	56
2.5.3	Summary of policy options related to limited exceptions to patent rights	56
2.6	Compulsory licensing and government use.....	57
2.6.1	TRIPS requirements for compulsory licences and government use.....	59
2.6.2	Compulsory licensing under South African law.....	61
2.6.2.1	Proceedings before the Commissioner of Patents	61
2.6.2.2	Determining adequate remuneration	62
2.6.2.3	Government use.....	63
2.6.2.4	Situations of national emergency or extreme urgency	65
2.6.2.5	Compulsory licences granted to remedy anti-competitive practices.....	66
2.6.2.6	Compulsory licences solely or largely for export	68
2.6.2.7	Other grounds for issuing compulsory licences	71
2.6.3	Patent revocation and acquisition by the State.....	72
2.7	Enforcement mechanisms, including remedies for infringement	73
2.7.1	Remedies available for infringement.....	73
2.7.2	Limiting the grant of interim interdicts	74
2.7.3	Limiting the grant of final interdicts.....	76
2.7.4	Summary of policy options related to remedies available for infringement.....	78
2.7.5	Counterfeit goods	79
3.	Analysis of South African Competition Policy	81

预览已结束，完整报告链接和二维码如下：

https://www.yunbaogao.cn/report/index/report?reportId=5_12798

